non-nucleoside analogue

non-nu·cle·o·side analogue

(nŏn-nōō′klē-ə-sīd′)
n.
Any of a structurally diverse group of antiviral agents, including delavirdine and nevirapine, that inhibit the enzyme reverse transcriptase and are used to treat HIV.
Mentioned in ?
References in periodicals archive ?
Overall, 68% initiated cART after meeting the criteria in government guidelines; all were started on a regimen containing a non-nucleoside analogue reverse transcriptase inhibitor, standard practice at the time.
Patients should have been exposed to at least two ARV, including: nucleoside analogue reverse transcriptase inhibitors (NRTIs), non-nucleoside analogue reverse transcriptase inhibitors (NNRTIs), and protease inhibitors (PIs).
Patterns of initial and last antiretroviral regimen used Number Frequency (n) (%) Initial regimen NRTI + PI 179 38.33 NRTI + boosted PI 6 1.28 NRTI + NNRTI 65 13.92 Monotherapy (AZT) 27 5.78 NRTI double therapy 191 40.89 Last regimen NRTI + PI 95 20.34 NRTI + boosted PI 166 35.55 NRTI + NNRTI 236 50.54 Monotherapy (AZT) 0 0 NRTI double therapy 9 1.93 NRTI = nucleoside analogue reverse transcriptase inhibitors, NNRTI = non-nucleoside analogue reverse transcriptase inhibitors, PI = protease inhibitors, AZT = zidovudine.
A second class of drugs which has recently become available is the non-nucleoside analogue reverse transcriptase inhibitors (NNRTls).
Subjects were allocated into two groups according to the drug class they were using at the time of the interview, namely protease inhibitors (PI) or non-nucleoside analogue reverse transcriptase inhibitors (NNRTI).
It can be inhibited either by nucleoside, nucleotide analogues or by non-nucleoside analogues.

Full browser ?